Basal and somatostatin-stimulated gastric intraluminal prostaglandin E2 in patients with gastric ulcer and with gastric adenocarcinoma.
The effect of somatostatin-14 (SST), at doses utilized in clinical practice, on gastric intraluminal prostaglandin (PG) E2 release was evaluated in 8 endoscopically normal subjects, in 6 patients with benign gastric ulcer and in 8 patients with gastric adenocarcinoma. In normal subjects, SST induced a significant increase in gastric intraluminal PGE2 concentration and output, whereas it did not augment the concentration and output of PGE2 in patients with gastric ulcer and with gastric cancer. The altered PG response to SST stimulation shown by gastric ulcer and gastric cancer patients may be related to a modified cell population in the gastric mucosa and/or to a defective regulation of this local gastric mucosal mediator.